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SHORT COMMUNICATION
Requirement for interleukin-1 to drive brain
inflammation reveals tissue-specific mechanisms
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The immune system is implicated in a wide range of disorders affecting the brain and
is, therefore, an attractive target for therapy. Interleukin-1 (IL-1) is a potent regulator of
the innate immune system important for host defense but is also associated with injury
and disease in the brain. Here, we show that IL-1 is a key mediator driving an innate
immune response to inflammatory challenge in the mouse brain but is dispensable in
extracerebral tissues including the lung and peritoneum.We also demonstrate that IL-1α
is an important ligand contributing to the CNS dependence on IL-1 and that IL-1 derived
from the CNS compartment (most likely microglia) is the major source driving this effect.
These data reveal previously unknown tissue-specific requirements for IL-1 in driving
innate immunity and suggest that IL-1-mediated inflammation in the brain could be
selectively targeted without compromising systemic innate immune responses that are
important for resistance to infection. This property could be exploited to mitigate injury-
and disease-associated inflammation in the brain without increasing susceptibility to
systemic infection, an important complication in several neurological disorders.
Keywords: innate immunity  interleukin-1 (IL-1)  neuroinflammation  neutrophil
 Additional supporting information may be found in the online version of this article at thepublisher’s web-site
Introduction
Inflammation is an integral component of the innate immune
response providing rapid host defense against infection. Nonmi-
crobial stimuli (e.g. cell death, hypoxia/ischaemia) can also trigger
inflammation, a response that in many conditions is implicated in
the exacerbation of tissue injury [1]. Identifying how to contain
Correspondence: Dr. Barry W. McColl
e-mail: barry.mccoll@roslin.ed.ac.uk
deleterious effects of inflammation during injury, without com-
promising host defense to infection, is essential.
A hallmark of an innate immune response is the accumula-
tion of neutrophils in inflamed tissue [2]. All vascularized tis-
sues are able to mount neutrophil-rich innate immune responses
if given appropriate stimulation. This includes the brain where we,
and others, have shown that dense neutrophil invasion occurs in
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response to injury or infection [3, 4]. Despite these similarities,
it is unclear whether the molecular mechanisms underpinning a
conserved innate immune response such as neutrophil recruitment
are comparable across tissues.
Interleukin-1 (IL-1)α/β are proinflammatory cytokines con-
sidered as key orchestrators of innate immune responses [5].
Production of IL-1 is induced by triggers associated with injury
or infection, including microbial ligands and damage-associated
molecular patterns [1]. IL-1 induces cytokines, chemokines,
growth factors, and vascular adhesion molecules which together
co-ordinate neutrophil trafficking and survival [5]. Our previous
work has shown the pathologic involvement of IL-1 in neu-
roinflammatory conditions such as stroke [6], which in part is
mediated by neutrophil-driven neurotoxicity [3]. We have also
demonstrated the therapeutic potential of anti-IL-1 approaches
for treating acute injury to the brain [7–9]; however, a limitation
of such an approach is the potential for increasing vulnerability
to infection through systemic suppression of innate immunity.
Here we compare the involvement of IL-1 in driving innate
immune responses in multiple tissues including the brain. Our
results show that the brain is uniquely dependent on IL-1 for
mounting an innate immune reaction.
Results and discussion
Differential requirements for IL-1 in driving brain
versus systemic innate immune responses
To determine if IL-1 is required to drive innate immune responses
in different tissues we stimulated inflammation with the bac-
terial endotoxin, LPS, in mice deficient in both IL-1 ligands
(IL-1α/β−/−) or wild-type controls. We used the accumulation of
neutrophils as a measure of the intensity of the inflammatory reac-
tion and assessed at timepoints coincidingwith peaks of neutrophil
influx established previously for the respective tissues. LPS stimu-
lated significant increases in neutrophil accumulation in lavage
fluid from the peritoneum, lung, and subcutaneous air-pouch
(Fig. 1A–C). Similar responses were observed in IL-1α/β−/− mice
indicating that IL-1 actions are dispensable for driving cellular
recruitment in multiple extracerebral tissues. In contrast, neu-
trophil recruitment to the brain in response to intrastriatal injec-
tion of LPS was significantly attenuated (70%) in IL-1α/β−/−
mice (Fig. 1D, E). These data suggest fundamental differences in
the requirement for IL-1 in regulating a key component of innate
immune responses in the brain in comparison to extracerebral
tissues. To our knowledge, this is the first unequivocal demonstra-
tion that IL-1 controls neutrophilic inflammation differently in the
brain in comparison to systemic tissues. We showed previously
that IL-1 deficiency [10] or administration of IL-1 receptor antag-
onist (IL-1Ra) [7] reduces neutrophil recruitment to the brain in
response to cerebral ischaemia. Alongside the present data, these
studies suggest IL-1 is a key driver of innate immune cell recruit-
ment to the brain in response to both microbial ligands and sterile
stimuli. Although we cannot be certain the pattern of IL-1 depen-
Figure 1. Brain-specific role of IL-1 during the innate immune response
(A–E). The innate immune response was triggered by LPS challenge in
four different tissues, in WT or IL-1α/β−/− mice and neutrophil accu-
mulation was determined by flow cytometry in (A) the peritoneum,
(B) lungs, (C) subcutaneous air pouch or (D) by immunostaining in the
brain. (E) Representative (n = 5 mice per group) immunofluorescence
images of SJC4+ neutrophils in brain parenchyma after LPS injection in
WT (left panel) and IL-1α/β−/− (right panel) mice, respectively. *p < 0.05,
p ** < 0.01, *** p < 0.0001; two-way ANOVA with Bonferroni correction.
Data are presented as mean + SD, n = 5 mice per group from a single
experiment. Scale bar = 100 μm.
dence would apply to stimuli other than LPS, our data are consis-
tent with previous studies showing that IL-1 was dispensable for
innate immune responses to various microbial-derived triggers in
other extracerebral tissues [11–13]. In contrast, IL-1 is a crucial
mediator of the response to sterile inflammatory stimuli such as
turpentine [14] and necrotic cell preparations [15] outside the
brain.
Tissue-specific activation of IL-1 or compensatory
pathways do not underlie brain dependence on IL-1
A potential reason for the brain-specific dependence on IL-1 could
be that LPS challenge triggers a different profile of inflammatory
mediators in the brain, for example, a response more restricted
to activating the IL-1 pathway relative to extracerebral sites. Mea-
surement of a range of cytokines and chemokines showed that
LPS induced a similar profile of inflammation across all tissue
C© 2014 The Authors. European Journal of Immunology published by
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sites (Supporting Information Fig. 1). LPS induced a significant
increase in the concentration of IL-1α (Supporting Information
Fig. 1A) and IL-1β (Supporting Information Fig. 1B) in all tissues
(with the exception of IL-1α in the peritoneum). These data show
that the unique requirement for IL-1 during brain inflammation
is not because of tissue differences in the capability to produce
IL-1 in response to LPS. The cytokine tumor necrosis factor-α can
compensate under inflammatory conditions where there is defi-
ciency of IL-1 [12]. LPS induced a significant increase in TNF-α
levels in the brain and in extracerebral tissues (Supporting Infor-
mation Fig. 1F) suggesting that the reliance on IL-1 in the brain
is not because there is a brain-specific inability to initiate alter-
native/parallel pathways such as via induction of TNF-α. Indeed,
in the brain, TNF-α levels in response to LPS were significantly
greater in IL-1α/β−/− compared with wild-type mice reinforcing
that the brain can activate compensatory pathways to IL-1. Over-
all, it therefore appears that themolecular profiles of inflammation
induced by LPS are similar in the brain and systemic tissues.
IL-1α mediates the brain-specific requirement for IL-1
in driving innate immunity
Our recent data implicated IL-1α as the key IL-1 agonist driv-
ing cerebrovascular inflammation [16]. We next determined the
functional contribution of IL-1α to the IL-1-dependent innate
immune reaction induced by intracerebral LPS challenge. Neu-
trophil recruitment to the brain was significantly reduced in
IL-1α−/− mice (Fig. 2). The magnitude of the effect was similar
to that observed in IL-1α/β−/− mice suggesting that IL-1α could
be the dominant ligand responsible for the dependence on IL-1.
However we cannot entirely exclude a role for IL-1β, particularly
given that intracerebral IL-1β administration or overexpression is
capable of inducing neutrophil infiltration to the brain and asso-
ciated chemokines [17, 18]. Intracerebral LPS caused changes
in microglial morphology and Iba1 immunostaining, consistent
with microglial activation e.g. hypertrophy of cell soma, retraction
of processes (Fig. 3A). IL-1α expression was markedly induced
on activated microglia in the hemisphere ipsilateral to injection
in wild-type mice but was completely absent in IL-1α−/− mice
(although microglia retained an activated morphology) (Fig. 3A).
Although IL-1α and IL-1β have overlapping roles under many
inflammatory conditions, recent evidence suggests that IL-1α is the
predominant ligand mediating inflammation early after inflamma-
tory insults to the brain, such as in response to cerebral ischaemia
[19, 20]. Outside the brain, sterile inflammatory stimuli such as
necrotic cell preparations that contain damage-associated molecu-
lar patterns trigger robust inflammatory responses including neu-
trophil recruitment that are dependent on IL-1α [15]. Thus, unlike
the brain, where the present and recent data point to a universal
dependence on IL-1, in extracerebral tissues there appears to be
a context-dependent requirement for IL-1 depending on whether
the stimulus is microbial or sterile.
Figure 2. Neutrophil infiltration into brain tissue is mediated by the
interluekin-1α ligand. (A) Neutrophil infiltration to brain parenchyma
induced by brain injection of LPS in WT and IL-1α−/− mice was deter-
mined by quantitative immunstaining. (B) Representative (n = 5 mice
per group) immunofluorescence images of SJC4+ neutrophils in brain
parenchyma after LPS injection in WT (left panel) and IL-1α−/− (right
panel) mice, respectively. *p < 0.05, p** < 0.01, ***p < 0.0001; two-way
ANOVA with Bonferroni correction. Data are presented as mean + SD,
n = 5 mice per group from a single experiment. Scale bar = 50 μm.
Intracerebral sources of IL-1 are responsible for the
brain-specific requirement for IL-1
Induction of IL-1α was not limited to the brain after intracerebral
LPS as we observed a significant increase in IL-1α (but not IL-1β)
concentration in blood plasma 6 h after intracerebral LPS injec-
tion (Fig. 3B). This induction was absent in platelet-depleted mice
indicating platelets as a key systemic source of IL-1α in this model
(Supporting Information Fig. 2) and responsive to intracerebral
LPS indirectly (e.g. as part of systemic acute phase response) or
directly via platelet expression of TLR4 [21]. We sought to deter-
mine the relative importance of intra- and extracerebral sources of
IL-1 in driving neutrophil recruitment to the brain in response to
intracerebral LPS challenge. In this model of brain inflammation
there is negligible disruption to the blood–brain barrier as shown
byminimal leakage of endogenous circulating IgG in the brain that
is comparable in veh- and LPS-injected mice. This restricts agents
administered systemically from entering the brain parenchyma
and provides a capability to selectively target IL-1 produced out-
side the brain. We first administered an anti-IL-1α neutralizing
antibody systemically to mice prior to LPS challenge. Lack of pen-
etration of the BBB was confirmed by the absence of immunos-
taining for rat IgG in anti- IL-1α IgG- or control IgG-injected
mice (Supporting Information Fig. 3A–B). Neutrophil accumula-
tion in the brain in response to LPS challenge was similar in both
anti- IL-1α and control IgG-treated mice (Fig. 3C). Given that the
distribution of the antibodies was contained systemically these
data implicate that IL-1α derived from cells in the brain is the
C© 2014 The Authors. European Journal of Immunology published by
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Figure 3. Brain microglia are the likely source of IL-1 required for neutrophil recruitment. (A) Representative images (n = 5 mice per group) of IL-1α
co-localisation with Iba1-positive microglia in the brain 24 h after LPS injection inWT (left panels) and IL-1α−/− (right panels) mice was determined
by immunostaining. (B) IL-1α and IL-1β concentrations in the blood plasma of mice 6 h after brain LPS injection were determined by cytometric
bead array. (C) Neutrophil infiltration into the brain following treatment with specific IL-1a neutralizing antibody (left panel), or the interleukin-1
receptor antagonist (IL-1Ra) (right panel) was determined by quantitative immunostaining. (D) Neutrophil accumulation in the brain following
simultaneous intracerebral injection of LPS with IL-1Ra or vehicle was determined by flow cytometry. *p < 0.05, p** <0 .01, two-way ANOVA with
Bonferroni correction. Data are presented as mean + SD, n = 5 mice per group from a single experiment. Scale bar = 50 μm
key source driving neutrophil recruitment. We substantiated this
finding using an alternative approach to selectively target sys-
temic IL-1 via intraperitoneal administration of IL-1Ra. As above,
we confirmed that IL-Ra did not reach the brain parenchyma (Sup-
porting Information Fig. 3C) Accumulation of neutrophils in the
brain in response to intracerebral LPS challenge was not altered
in mice administered IL-1Ra systemically (Fig. 3C) which fur-
ther supports that the brain compartment is the critical source
of IL-1. In contrast, IL-1Ra administered directly into the brain
significantly attenuated neutrophil accumulation in response to
intracerebral LPS (Fig. 3D). As described above intracerebral LPS
challenge induced expression of IL-1α which was exclusively local-
ized to microglia. Thus, microglial-derived IL-1 appears to be the
key source responsible for the unique dependence on IL-1 in this
model.
Concluding remarks
Immunosuppression and increased susceptibility to infection are
potentially unwanted adverse effects of immunomodulatory treat-
ments targeting injury or disease-associated inflammation. This is
a particular issue for brain disorders, most notably acute injuries
such as stroke where systemic infection is a common complica-
tion and leading cause of mortality [22]. The ability to selec-
tively modify pathologic inflammation in the injured brain without
overly suppressing systemic immunity would be advantageous.
Our present data highlight that IL-1 is a target that could ful-
fil these criteria. Neutrophil recruitment is a hallmark of innate
immune responses and essential for effective defense against bac-
terial infection [2]. We and others have shown previously that
neutrophils contribute to exacerbation of injury in the brain [3, 4].
Our present data reveal that blocking IL-1α activity can markedly
reduce neutrophil recruitment to the inflamed brain but, in con-
trast, IL-1 is completely dispensable for neutrophil recruitment to
multiple extracerebral tissues. This suggests that anti-IL-1 inter-
ventions, at least given acutely, may have the capacity to limit
injury-amplifying inflammation in the brain without markedly
weakening systemic innate immunity needed for host defense.
In support, recent clinical trials testing the safety of recombinant
human IL-1Ra after stroke [9] or subarachnoid hemorrhage [23]
reported a lower than average incidence of infection. Moreover,
there is some indication that IL-1Ra may actually protect against
systemic immunosuppressive responses to stroke [24].
In conclusion, we have demonstrated dependence on IL-1 for
driving an innate immune response to inflammatory challenge in
the brain that contrasts with IL-1-independence in extracerebral
tissues. We believe these properties could be exploited therapeu-
C© 2014 The Authors. European Journal of Immunology published by
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tically to minimize systemic immunosuppressive complications of
anti-inflammatory therapy in neurological disorders.
Materials and methods
Animals
Experiments were performed on male 8–10 week-old C57Bl/6J,
IL-1αβ−/− and IL-1α−/− mice and adhered to the UK Animals
(Scientific Procedures) Act 1986.
Inflammatory challenge
Peritoneal inflammation model
Mice were injected intraperitoneally with 1 mg/kg LPS from
Escherichia coli O127:B8 (Sigma-Aldrich, Dorset, UK) or vehicle
(PBS) in a volume of 8 mL/kg. Peritoneal lavage was performed
at 6 h using 5 mL PBS containing 0.1% BSA and 1 mM EDTA.
Broncho-alveolar inflammation model
Mice were exposed to aerosolized LPS (2 mg/mL) or vehicle
(saline) for 20 min and broncho-alveolar lavage performed after
6 h with 1 mL of PBS containing 0.1% BSA and 1 mM EDTA.
Air pouch inflammation model
Dorsal air pouches were created in conscious mice as described
previously [25]. At day 7, 1 mL of LPS (1 mg/mL) or vehicle
(PBS) was injected into the air pouch. After 6 h air pouch lavage
was performed using 4 mL PBS, with 0.1% BSA and 1 mM EDTA.
Cerebral inflammation model
Animals were anesthetized with isoflurane (3%) in O2
(200 mL/min) and N2O (400 mL/min) and craniectomy per-
formed. Mice were injected intracerebrally with 1 μL LPS
(4 mg/mL), via a glass microneedle (co-ordinates from bregma:
anterior–posterior −0.0 mm, lateral −2.0 mm, ventral −2.5 mm.
Rate = 0.5 μL/min). Recombinant human IL-1Ra (10 μg) or
placebo were coinjected with LPS. Mice were transcardially per-
fused with saline at 6 h and brain tissue collected for CBA analy-
sis or perfuse-fixed (saline followed by paraformaldehyde 4%) at
24 h for tissue sectioning.
Flow cytometry
Lavage fluid cell suspensions (200 μL) were incubated for 20 min
with rat anti-mouse CD16/CD32 to block nonspecific Fc binding
then stained with anti-mouse Ly-6G (1A8) for 30 min. Brain cell
suspensions were prepared by enzymatic digestion and density
gradient centrifugation and cells incubated with anti-CD16/CD32
before staining with anti-mouse Ly6G-Pacific Blue. Absolute cell
counts were determined by the addition of 50 μL fluorescent
counting beads (Invitrogen, Paisley, UK). Flow cytometry was per-
formed on a CyAnTM ADP Flow Cytometer (Dako UK Ltd, Ely, UK)
or BD Fortessa (BD Biosciences USA) and data was analyzed using
Summit 4.0 software.
Immunostaining
Immunohistochemistry was performed on coronal brain sections
using standard protocols. Anti-neutrophil (SJC4, rabbit anti-
mouse) primary antibody (1:50 000; kindly provided by Drs. D
Anthony and S Campbell, University of Oxford, UK) was used to
stain for neutrophils and anti-Iba1 for microglia. Neutrophil num-
bers were quantified in three regions of interest (cerebral cortex,
injection site, and ventral striatum) using a 10 × 10 mm graticule
at 20× magnification and expressed as the sum of the counts in
each region of interest.
Cytometric bead array
Cytokine concentrations in plasma and lavage samples were
determined using mouse-specific CBA flex sets (BD Pharmingen,
Oxford, UK) following manufacturer’s guidelines with an opti-
mized 1:5 dilution of concentrations. Acquisition was undertaken
using a BD FACSArrayTM Bioanalyzer System (BD Biosciences,
Oxford, UK), and results determined using FCAP ArrayTM software
(Soft Flow, Burnsville, Minnesota, USA).
Systemic IL-1 interventions
Mice were injected i.p. with anti-IL-1α or IgG isotype control
(4 mg/kg), 24 h before intracerebral injection of LPS. IL-1Ra
(10 mg/kg) or saline was administered i.p. 1 h before and 2 h
after LPS injection. Doses were chosen based on ND50 and our
previous data on cytokine responses to LPS.
Statistics
Data are expressed as mean (± SD). Differences between groups
were analyzed using two-way ANOVA with post-hoc Bonferroni
correction. Differences were considered statistically significant at
p < 0.05. Sample sizes were estimated using power analysis on
data from pilot experiments. Mice were randomized to treatment
groups.
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